Results 221 to 230 of about 52,894 (243)
Some of the next articles are maybe not open access.

Efficacy of adjuvant chemotherapy with 5-Fu/leucovorin and 5-Fu/levamisole in colon cancer

Gastroenterology, 1998
Previous studies have demonstrated the positive impact of adjuvant chemotherapy with 5-FU/levamisole on survival of patients with stage I11 colon cancer. In metastatic cancer, biochemical modulation of 5-FU leads to increased remission rates. Therefore, the effects of 5-FU/leucovorin (450 and 100 mg/m 2 i,v.
R. Porschen   +6 more
openaire   +1 more source

Selective delivery of 5-fluorouracil (5-FU) to i.p. tissues using 5-FU microspheres in rats

Anti-Cancer Drugs, 1997
A new formulation has been developed for the delivery of 5-fluorouracil (5-FU) in treating peritoneal carcinomatosis. The new formulation (5-FU-MS) involves the incorporation of 5-FU into microspheres composed of a poly(glycolide-co-lactide) matrix. The incorporated 5-FU is released slowly over a 3 week period. We investigated the drug distribution and
A, Hagiwara   +11 more
openaire   +2 more sources

Intraoperative Treatment with 5-FU

2018
The use of 5-FU and its effectiveness in the treatment of keloid and hypertrophic scar have been evidenced in several studies reaching very favorable results. Currently, the use has been directed as therapy on healing states with poor evolution already established, where the inhibitory effect of 5-FU on fibroblastic proliferation results in the ...
Guillermo Blugerman   +5 more
openaire   +1 more source

The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.

Digestive diseases and sciences, 2013
Acquired resistance to 5-fluorouracil (5-FU) is a serious therapeutic obstacle in advanced hepatocellular carcinoma (HCC) patients.To investigate whether nuclear factor erythroid 2-related factor 2 (Nrf2) was associated with drug resistance in 5-FU resistant Bel-7402 (Bel-7402/5-FU) cells, and if sorafenib, an oral multikinase inhibitor targeting the ...
Suna, Zhou   +4 more
openaire   +1 more source

Successful treatment with 5-Fu

Ophthalmology, 2003
Barry A, Schechter, Robert S, Nagler
openaire   +2 more sources

[Chemosensitivity testing for 5-FU and 5-FU derivatives using subrenal capsule assay].

Gan to kagaku ryoho. Cancer & chemotherapy, 1987
An evaluation was made, using in vivo subrenal capsule (SRC) assay, of the chemosensitivity of 12 human neoplastic tissues including 7 gastric cancers, 2 colo-rectal cancers, 2 lung cancers and 1 breast cancer, exposed to 5-fluorouracil (5-FU) and the 5-FU derivatives: tegafur (FT), UFT and hexylcarbamoyl-5-FU (HCFU).
H, Anai   +4 more
openaire   +1 more source

[Comparative clinical study on 5-FU concentrations for oral HCFU and i.v. 5-FU].

Gan to kagaku ryoho. Cancer & chemotherapy, 2000
Using the cross-over method, the same patients were administered continuous intravenous injections of 5-FU and HCFU, an oral derivative of 5-FU widely used for breast and colon cancer in Japan. The pharmacokinetics of 5-FU in blood of both drugs were then compared.
M, Miyauchi   +4 more
openaire   +1 more source

[5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].

Gan to kagaku ryoho. Cancer & chemotherapy, 2003
5-FU hepato-arterial infusion (HAI) is powerful chemotherapy for liver metastases of colorectal cancers. Event though hepatic lesions are controlled by 5-FU HAI, we have found that extra-hepatic lesions are the limiting factor for colorectal cancer patients. General chemotherapy is necessary in addition to 5-FU HAI.
Michio, Maruyama   +6 more
openaire   +1 more source

[Cisplatin/5-FU versus carboplatin/5-FU. 5 year follow-up].

HNO, 1995
Between March 1986 and October 1987, 73 patients with advanced squamous cell carcinomas of the head and neck underwent initial chemotherapy before surgery and/or radiotherapy. Chemotherapy consisted of three courses of carboplatin/5-FU or cisplatin/5-FU. Pretreatment tumor states, remission rates and ages of the patients were comparable. Carboplatin as
O, Ebeling   +4 more
openaire   +1 more source

THE COST OF 5-FU

Plastic and Reconstructive Surgery, 2001
openaire   +2 more sources

Home - About - Disclaimer - Privacy